Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.32 |
| ▸ | BMP1 | P13497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26429181 | 1.00 | ALOX15 (0.35) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL29140277 | 0.98 | ALOX15 (0.34) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL29768848 | 0.85 | CTSC (0.39) | BLMKMT2A | |
| SCHEMBL22731801 | 0.85 | CTSC (0.39) | BLMKMT2A | |
| SCHEMBL16181956 | 0.85 | CTSC (0.39) | BLMKMT2A | |
| SCHEMBL26429623 | 0.81 | BMP1 (0.38) | BMP1 | |
| SCHEMBL24943424 | 0.81 | CTSK (0.33) | CTSK | |
| SCHEMBL11363519 | 0.79 | DPP4 (0.38) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL22387766 | 0.79 | CTSK (0.39) | DPP4DPP8DPP9CTSK | |
| SCHEMBL23656864 | 0.79 | CTSK (0.33) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127524-A1 | FILAMENTOUS NANOSTRUCTURES AND THEIR USE FOR TREATMENT OF PULMONARY DISEASE | NATIONAL SCIENCE FOUNDATION | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127524-A1 | FILAMENTOUS NANOSTRUCTURES AND THEIR USE FOR TREATMENT OF PULMONARY DISEASE | MFAP1, DIAPH1, SEPTIN7 | ALOX15 2891/4885BLM 276/4885PMP22 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.